Emergent BioSolutions, Inc. (NYSE:EBS) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 05:00 pm ET
Ladies and gentlemen thank you for standing by and welcome to the Third Quarter 2019 Emergent BioSolutions Inc. Earnings Conference call. [Operator Instructions] As a reminder today's program is being recorded.
And now I'd like to introduce your host for today's program Bob Burrows Vice President of Investor Relations. Please go ahead.
Robert G. Burrows
Thank you, Jonathan and good afternoon everyone. Again it's Bob Burrows VP of Investor Relations for the company. Thank you for joining us today as we discuss the operational and financial results for the third quarter and nine months of 2019. As is customary today's call is opened to all participants and in addition the call is being recorded and is copyrighted by Emergent BioSolutions. Participating on the call with prepared comments will be Bob Kramer President and Chief Executive Officer; and Rich Lindahl Chief Financial Officer. Other members of the senior team are present and available during the Q&A session that will follow our prepared comments. Before beginning I will remind everyone that during today's call either on our prepared comments or the Q&A session management may make projections and other forward-looking statements related to our business future events our prospects or future performance. These forward-looking statements are based on our current intentions beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should therefore realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize actual results could differ materially from our expectations. Any forward-looking statement speaks only as of the date of this conference call and except as required by law we do not undertake to update any forward-looking statements to reflect new information events or circumstances. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the SEC when evaluating our forward-looking statements. During our prepared comments as well as during the Q&A session we may also refer to certain non-GAAP financial measures that involve adjustments to GAAP figures in order to provide greater transparency regarding Emergent's operating performance. Please refer to the tables found in today's press release regarding our use of adjusted net income EBITDA and adjusted EBITDA and the reconciliations between our GAAP financial measures and these non-GAAP financial measures. For the benefit of those who may be listening to the replay of the webcast this call was held and recorded on November 6 2019. Since then Emergent may have made announcements related to topics discussed during today's call. You are once again encouraged to refer to our most recent press releases and SEC filings all of which may be found on the Investors homepage of our website. And with that introduction I would now like to turn the call over to Bob Kramer Emergent BioSolutions' President and CEO. Bob?
Robert G. Kramer Sr.
Thank you, Bob and good afternoon to everyone. Thank you for joining our call today. As with last quarter I'll provide a brief overview of our financial performance for the quarter and year-to-date periods.